Carcinogenesis · 2017 · 15 citations · 42 references
Life SciencesMedicinal ChemistryPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCell Signaling DisruptionMelanoma PharmacotherapyOncogenic Signaling PathwaysSignal Transduction In CancerWnt SignalingCancer Cell Proliferation InhibitionCanonical Beta-catenin SignalingCanonical Wnt Beta-catenin PathwayCanonical Wnt PathwayCanonical Wnt SignalingGlycogen Synthase Kinase 3 SignalingWnt Signal TransductionWnt Signaling Disruption
1-Benzyl-indole-3-carbinol (1-benzyl-I3C), a synthetic analogue of the crucifer-derived natural phytochemical I3C, displayed significantly wider sensitivity and anti-proliferative potency in melanoma cells than the natural compound. Unlike I3C, which targets mainly oncogenic BRAF-expressing cells, 1-benzyl-I3C effectively inhibited proliferation of melanoma cells with a more extensive range of mutational profiles, including those expressing wild-type BRAF. In both cultured melanoma cell lines and in vivo in melanoma cell-derived tumor xenografts, 1-benzyl-I3C disrupted canonical Wnt/β-catenin signaling that resulted in the downregulation of β-catenin protein levels with a concomitant increase in levels of the β-catenin destruction complex components such as glycogen synthase kinase-3β (GSK-3β) and Axin. Concurrent with the inhibition of Wnt/β-catenin signaling, 1-benzyl-I3C strongly downregulated expression of the melanoma master regulator, microphthalmia-associated transcription factor isoform-M (MITF-M) by inhibiting promoter activity through the consensus lymphoid enhancer factor-1 (LEF-1)/T-cell transcription factor (TCF) DNA-binding site. Chromatin immunoprecipitation revealed that 1-benzyl-I3C downregulated interactions of endogenous LEF-1 with the MITF-M promoter. 1-Benzyl-I3C ablated Wnt-activated LEF-1-dependent reporter gene activity in a TOP FLASH assay that was rescued by expression of a constitutively active form of the Wnt co-receptor low-density lipoprotein receptor-related protein (LRP6), indicating that 1-benzyl-I3C disrupts Wnt/β-catenin signaling at or upstream of LRP6. In oncogenic BRAF-expressing melanoma cells, combinations of 1-benzyl-I3C and Vemurafenib, a clinically employed BRAF inhibitor, showed strong anti-proliferative effects. Taken together, our observations demonstrate that 1-benzyl-I3C represents a new and highly potent indolecarbinol-based small molecule inhibitor of Wnt/β-catenin signaling that has intriguing translational potential, alone or in combination with other anti-cancer agents, to treat human melanoma.
42
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Osamu Tetsu, Frank McCormick · Nature · 1999 · 3.6K citations
Medicine, Cell Biology, Oncology +14
A Landscape of Driver Mutations in Melanoma
Eran Hodis, Ian R. Watson, Gregory V. Kryukov et al. · Cell · 2012 · 2.6K citations · Full text
A role for Wnt signalling in self-renewal of haematopoietic stem cells
Tannishtha Reya, Andrew W. Duncan, Laurie Ailles et al. · Nature · 2003 · 2.1K citations